MetaCap

Apollomics Inc. Class A (APLM)

NASDAQ: APLMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

15.54-1.16 (-6.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

APLM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$45.28M
EPS (TTM)
-$0.25
52-week range
12.58 – 28.29
Day range
15.54 – 16.51
Volume / Avg
4.07K / 11.07K
Beta
—

52-week range

$12.58$28.29

APLM stock today

On Nov 20, APLM ended the session at $15.54, shedding $1.16 (6.92%), versus the S&P 500's 3.70% decline. Trading was light, with 4.07K shares changing hands, about 37% of the average daily volume. At this level, APLM sits near the bottom of its 52-week range of $12.58 to $28.29: 45.1% below the high, set on Sep 3, 2026 and 23.5% above the low.

APLM is down 16.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 7.4%. Apollomics has posted a net loss over the last twelve months (EPS of -$0.25), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Apollomics

Company profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Hung-Wen Chen
Headquarters
Foster City, CA
Employees
14

Financial highlights

Full financials

In fiscal 2024, Apollomics generated $0 in revenue, up 0.0% from fiscal 2023. Apollomics reported a net loss of $53.9 million, compared with a loss of $172.6 million a year earlier. Diluted earnings per share came in at -$52.80.

Apollomics annual revenue, net income and EPS
Fiscal yearFY 2024FY 2023FY 2022FY 2021FY 2020
Revenue$0$0$0$0$0
Growth—————
Net income$-53.86M$-172.60M$-240.81M$-94.80M$-74.82M
EPS (diluted)$-52.80$-231.99$-844.95$-3.37$-0.21

Apollomics peers

Health Care sector
APLM peer companies
CompanyPrice% ChgMarket capCompare
RNXTRenovoRx Inc.0.942-10.29%$45.45Mvs APLM
QUCYQuantum Cyber N.V.0.512-7.25%$44.67Mvs APLM
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs APLM
GANXGain Therapeutics Inc.0.9994-4.82%$44.50Mvs APLM
MISTMilestone Pharmaceuticals Inc.0.3711-7.06%$46.20Mvs APLM
TNXPTonix Pharmaceuticals Holding Corp.2.38-6.67%$46.25Mvs APLM
ANVSAnnovis Bio Inc.0.7113-4.96%$44.12Mvs APLM
VRCAVerrica Pharmaceuticals Inc.2.74-5.03%$47.07Mvs APLM

Indexes, lists and sector

Apollomics stock FAQ

What is Apollomics's stock price today?

APLM last traded at $15.54 as of Nov 20, 4:00 PM EST, down 6.92% on the day. Prices are delayed at least 15 minutes.

Does Apollomics pay a dividend?

No. Apollomics does not currently pay a regular cash dividend.

Who is Apollomics's CEO?

Mr. Hung-Wen Chen is the chief executive officer of Apollomics Inc. Class A, which has about 14 employees.

Has APLM ever split its stock?

Yes. The most recent APLM stock split was a 1-for-100 split on Nov 25, 2024.

What is the APLM 52-week high?

The 52-week high for APLM is $28.29 and the 52-week low is $12.58. The stock is currently 45.1% below its high.

Compare APLM